{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/ankylosing-spondylitis/","result":{"data":{"firstChapter":{"id":"1318829b-e445-59f5-8079-ced63414cf7e","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field df678ecf-2dc6-4da2-9761-d379b10f663b --><h1>Ankylosing spondylitis: Summary</h1><!-- end field df678ecf-2dc6-4da2-9761-d379b10f663b -->","htmlStringContent":"<!-- begin item e71954c0-4de4-406e-95b7-3fde14ee210c --><!-- begin field fc51ceb8-ca6c-40bf-b934-74dd89654f90 --><ul><li>Spondyloarthritis is a term describing a group of clinically heterogeneous inflammatory rheumatologic conditions. It may be axial, affecting the sacroiliac joints and the spine, or peripheral.<ul><li>Ankylosing spondylitis (radiographic axial spondyloarthritis) is axial spondyloarthritis characterized by sacroiliitis on x-ray. Axial spondyloarthritis can also occur in the absence of x-ray changes and this is classified as non-radiographic axial spondyloarthritis (although changes may be visible on magnetic resonance imaging). Both conditions have similar presentations. </li></ul></li><li>Features of ankylosing spondylitis include:  <ul><li>Chronic back pain (often inflammatory in nature) and stiffness that improves with exercise, not rest.</li><li>Sacroiliac joint and spinal fusion. New bone formation leads to sacroiliac joint ankylosis and the formation of syndesmophytes (bony growths in intervertebral joint ligaments) in the spine.</li><li>Arthritis and enthesitis — the most common peripheral manifestations (predominantly in the lower limbs with asymmetrical distribution). </li><li>Dactylitis (swelling of a finger or toe).</li><li>Fatigue. </li><li>Extra-articular manifestations (for example anterior uveitis, psoriasis, inflammatory bowel disease). </li></ul></li><li>Prevalence of ankylosing spondylitis is believed to range from 0.05% to 0.23% and it is around twice as common in men as women. It most often begins between 20 and 30 years of age.</li><li>Complications include:<ul><li>Spinal fractures.</li><li>Hip involvement.</li><li>Osteoporosis.</li><li>Anterior uveitis (iritis).</li><li>Adverse effects of treatment.</li><li>Decreased quality of life.</li></ul></li><li>If ankylosing spondylitis is suspected, referral to a rheumatologist should be arranged.<ul><li>Treatment with a nonsteroidal anti-inflammatory drug (NSAID) should be considered while awaiting referral.</li></ul></li><li>Referral to rheumatology of suspected cases of ankylosing spondylitis will allow the rheumatologist to: <ul><li>Confirm the diagnosis.</li><li>Review current treatment including any need for biological DMARDs.</li><li>Refer to physiotherapy for an individualised, structured exercise programme.</li><li>Refer to a specialist therapist (for example occupational therapy or physiotherapy) if the person has difficulty with activities of daily living.</li><li>Arrange regular osteoporosis assessments (every 2 years).</li><li>Make arrangements for follow up and monitoring, which may be a shared care arrangement.</li></ul></li><li>Follow up of a person with confirmed ankylosing spondylitis should include:<ul><li>Monitoring of disease activity, progression, and response to treatment (including adverse effects).</li><li>Ensuring modifiable cardiovascular risk factors are managed if present.</li><li>Ensuring the person receives an assessment for osteoporosis every 2 years.</li></ul></li></ul><!-- end field fc51ceb8-ca6c-40bf-b934-74dd89654f90 --><!-- end item e71954c0-4de4-406e-95b7-3fde14ee210c -->","topic":{"id":"228aa309-0970-5ae0-a937-1a670214e066","topicId":"0752afda-bf5b-48c4-b4af-e842f0a9b229","topicName":"Ankylosing spondylitis","slug":"ankylosing-spondylitis","aliases":[],"chapters":[{"id":"1318829b-e445-59f5-8079-ced63414cf7e","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"28658e82-53d5-5798-84bf-7e67cc233b06","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"bc7876cf-e413-557d-b763-1b8198ae3cb7","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"b83be00a-c774-50aa-b8be-a04912f19bd5","slug":"changes","fullItemName":"Changes"},{"id":"ecb29915-59e9-5752-9bbb-fc44515688b3","slug":"update","fullItemName":"Update"}]},{"id":"81161324-4d7b-5419-85a9-dae9f57fa83b","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"c127b8df-f565-5637-adb8-bafbfd767c40","slug":"goals","fullItemName":"Goals"},{"id":"091c0d27-63a5-548e-8f08-5bfb48e416a7","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f9ca120c-2183-5429-9706-101fc20540e1","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"58752ac1-77db-5b74-8e2e-bf0081dd74fd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ffa55c0b-7b3d-583c-8a67-f0372230cbf9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4c33c07f-65b3-572b-b4c0-1eecffd16191","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f4a7a8d2-8847-5779-9892-e4867ecaacdd","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"8c9e7d3f-07eb-5b06-9f42-67f6c18e4ce2","slug":"definition","fullItemName":"Definition"},{"id":"64b026f5-a69f-5ef8-800d-7aee9ac65509","slug":"causes","fullItemName":"Causes"},{"id":"fc3d12c0-7b54-576d-ba75-e8570df23bf0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ff462ad5-64de-5366-801e-9806962bcf65","slug":"complications","fullItemName":"Complications"},{"id":"76129f0b-5489-511d-bc1d-565b990f4fb8","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a54d37d1-407b-50c4-b5e8-c98891ee1e00","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"6a2b7eca-b47b-5a11-9909-91a6aea6835a","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ea0d0799-6976-5240-92c5-4623f9074fda","slug":"investigations","fullItemName":"Investigations"},{"id":"58c6e66c-a8a5-56c9-8c47-7127807d9c73","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5f2d8235-d927-54d7-bd0a-4ec15e3336b8","slug":"management","fullItemName":"Management","subChapters":[{"id":"0a3569b1-7ede-51ad-abdd-77173b02733e","slug":"suspected-ankylosing-spondylitis","fullItemName":"Scenario: Suspected ankylosing spondylitis"},{"id":"3e6db8e8-b2dc-5a7a-9fe2-0a341c7c963d","slug":"confirmed-ankylosing-spondylitis","fullItemName":"Scenario: Confirmed ankylosing spondylitis"}]},{"id":"b82cc559-18dd-500a-add0-dde6d8b59e63","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"76b292a6-865e-5dcd-9885-3e235e7664a4","slug":"oral-nsaids","fullItemName":"Oral NSAIDs"},{"id":"113dcc0f-4841-54a0-9101-a64009316e7c","slug":"proton-pump-inhibitors-ppis","fullItemName":"Proton pump inhibitors (PPIs)"},{"id":"52667269-49b0-5132-839c-67d58b9480db","slug":"paracetamol-codeine","fullItemName":"Paracetamol and codeine"}]},{"id":"59c2b871-f61e-5fb4-a894-cae5bdeda4bd","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"80288a50-5bef-5779-8bf9-7d8abf169080","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"932977c5-3d44-5c3b-8787-7de309af3820","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"eb5fa8b8-2845-567c-ab0a-2274329dfc51","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c4153414-1fd0-5779-a348-78ee4ab85730","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"12b49dd2-6a18-5e19-8960-15901b6a91b7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"83d1e8ec-8cac-5c4a-ac1b-758b9b2501bb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"67d800ae-fb2a-559a-89de-a4813d740021","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"228aa309-0970-5ae0-a937-1a670214e066","topicId":"0752afda-bf5b-48c4-b4af-e842f0a9b229","topicName":"Ankylosing spondylitis","slug":"ankylosing-spondylitis","aliases":[],"topicSummary":"Ankylosing spondylitis is a chronic inflammatory rheumatic disease of unknown cause and varying clinical presentation.","lastRevised":"Last revised in May 2019","nextPlannedReviewBy":"2024-05-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2024-04","nextPlannedReviewByDisplay":"April 2024","specialities":[{"id":"f8332083-731e-50fe-a895-030315ce6083","name":"Musculoskeletal","slug":"musculoskeletal"}],"chapters":[{"id":"1318829b-e445-59f5-8079-ced63414cf7e","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"28658e82-53d5-5798-84bf-7e67cc233b06","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"bc7876cf-e413-557d-b763-1b8198ae3cb7","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"b83be00a-c774-50aa-b8be-a04912f19bd5","slug":"changes","fullItemName":"Changes"},{"id":"ecb29915-59e9-5752-9bbb-fc44515688b3","slug":"update","fullItemName":"Update"}]},{"id":"81161324-4d7b-5419-85a9-dae9f57fa83b","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"c127b8df-f565-5637-adb8-bafbfd767c40","slug":"goals","fullItemName":"Goals"},{"id":"091c0d27-63a5-548e-8f08-5bfb48e416a7","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f9ca120c-2183-5429-9706-101fc20540e1","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"58752ac1-77db-5b74-8e2e-bf0081dd74fd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ffa55c0b-7b3d-583c-8a67-f0372230cbf9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4c33c07f-65b3-572b-b4c0-1eecffd16191","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f4a7a8d2-8847-5779-9892-e4867ecaacdd","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"8c9e7d3f-07eb-5b06-9f42-67f6c18e4ce2","slug":"definition","fullItemName":"Definition"},{"id":"64b026f5-a69f-5ef8-800d-7aee9ac65509","slug":"causes","fullItemName":"Causes"},{"id":"fc3d12c0-7b54-576d-ba75-e8570df23bf0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ff462ad5-64de-5366-801e-9806962bcf65","slug":"complications","fullItemName":"Complications"},{"id":"76129f0b-5489-511d-bc1d-565b990f4fb8","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a54d37d1-407b-50c4-b5e8-c98891ee1e00","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"6a2b7eca-b47b-5a11-9909-91a6aea6835a","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ea0d0799-6976-5240-92c5-4623f9074fda","slug":"investigations","fullItemName":"Investigations"},{"id":"58c6e66c-a8a5-56c9-8c47-7127807d9c73","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5f2d8235-d927-54d7-bd0a-4ec15e3336b8","slug":"management","fullItemName":"Management","subChapters":[{"id":"0a3569b1-7ede-51ad-abdd-77173b02733e","slug":"suspected-ankylosing-spondylitis","fullItemName":"Scenario: Suspected ankylosing spondylitis"},{"id":"3e6db8e8-b2dc-5a7a-9fe2-0a341c7c963d","slug":"confirmed-ankylosing-spondylitis","fullItemName":"Scenario: Confirmed ankylosing spondylitis"}]},{"id":"b82cc559-18dd-500a-add0-dde6d8b59e63","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"76b292a6-865e-5dcd-9885-3e235e7664a4","slug":"oral-nsaids","fullItemName":"Oral NSAIDs"},{"id":"113dcc0f-4841-54a0-9101-a64009316e7c","slug":"proton-pump-inhibitors-ppis","fullItemName":"Proton pump inhibitors (PPIs)"},{"id":"52667269-49b0-5132-839c-67d58b9480db","slug":"paracetamol-codeine","fullItemName":"Paracetamol and codeine"}]},{"id":"59c2b871-f61e-5fb4-a894-cae5bdeda4bd","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"80288a50-5bef-5779-8bf9-7d8abf169080","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"932977c5-3d44-5c3b-8787-7de309af3820","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"eb5fa8b8-2845-567c-ab0a-2274329dfc51","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c4153414-1fd0-5779-a348-78ee4ab85730","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"12b49dd2-6a18-5e19-8960-15901b6a91b7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"83d1e8ec-8cac-5c4a-ac1b-758b9b2501bb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"67d800ae-fb2a-559a-89de-a4813d740021","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"228aa309-0970-5ae0-a937-1a670214e066"}},"staticQueryHashes":["3666801979"]}